About Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie
Clinical Trials at Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie
During the past decade, Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 3 clinical trials were completed, i.e. on
average, 300% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie"
#1 collaborator was "AbbVie" with 1 trials as a collaborator, "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "German CLL Study Group" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 4 trials.
Clinical Trials Conditions at Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie
According to Clinical.Site data, the most researched conditions in "Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie" are
"B-cell Lymphoma" (1 trials), "Diffuse Large B-Cell Lymphoma" (1 trials), "Lymphocytic Leukemia, Chronic" (1 trials) and "Non-Hodgkin's Lymphoma" (1 trials). Many other conditions were trialed in "Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie" in a lesser frequency.
Clinical Trials Intervention Types at Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie
Most popular intervention types in "Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie" are "Drug" (4 trials). Other intervention types were less common.
The name of intervention was led by "Rituximab" (3 trials), "Obinutuzumab" (2 trials), "Bevacizumab" (1 trials), "CHOP" (1 trials) and "Chemotherapy (Induction Period)" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie
The vast majority of trials in "Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie" are
4 trials for "All" genders.
Clinical Trials Status at Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie
Currently, there are NaN active trials in "Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie".
undefined are not yet recruiting,
undefined are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 1 completed trials in Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 4 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".